Products - Liver cancers | Topic | NICE

Showing 6 products

Date | Title

Status: In developmentRemove ‘Status: In development’ filter

Nivolumab for adjuvant treatment of high-risk hepatocellular carcinoma after liver resection or ablation [ID3858]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
17 July 2024
Durvalumab with tremelimumab for untreated advanced or unresectable hepatocellular carcinoma [ID2725]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
19 August 2025
Suspected Cancer: recognition and referral (update)
Status:
In development
Programme:
NICE guideline
Expected publication date:
13 March 2026
Doxorubicin nanoparticles for previously treated advanced hepatocellular carcinoma [ID1314]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Lenvatinib with pembrolizumab and transarterial chemoembolization for untreated localised hepatocellular carcinoma [ID5117]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Atezolizumab with bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence [ID6148]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC